ELEKT-D: Electroconvulsive Therapy (ECT) vs. Ketamine in Patients With Treatment Resistant Depression (TRD) View Homepage


Ontology type: schema:MedicalStudy     


Clinical Trial Info

YEARS

2017-2022

ABSTRACT

The goal of the study is to conduct a comparative randomized trial of electroconvulsive therapy (ECT) vs. ketamine for patients with treatment resistant depression (TRD) in a real world setting with patient reported outcomes as primary and secondary outcome measures. Detailed Description Patients with treatment resistant depression who meet all inclusion criteria and do not meet any exclusion criteria will be randomized to either electroconvulsive therapy (ECT) three times per week or ketamine infusion two times per week. Patients will answer questionnaires about their symptoms prior to treatments. The acute treatment phase of the study will last three to five weeks. Depending on response to treatment, some patients will be followed for an additional six months. More... »

URL

https://clinicaltrials.gov/show/NCT03113968

Related SciGraph Publications

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3053", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "description": "The goal of the study is to conduct a comparative randomized trial of electroconvulsive therapy (ECT) vs. ketamine for patients with treatment resistant depression (TRD) in a real world setting with patient reported outcomes as primary and secondary outcome measures.\n\nDetailed Description\nPatients with treatment resistant depression who meet all inclusion criteria and do not meet any exclusion criteria will be randomized to either electroconvulsive therapy (ECT) three times per week or ketamine infusion two times per week. Patients will answer questionnaires about their symptoms prior to treatments. The acute treatment phase of the study will last three to five weeks. Depending on response to treatment, some patients will be followed for an additional six months.", 
    "endDate": "2022-04-01T00:00:00Z", 
    "id": "sg:clinicaltrial.NCT03113968", 
    "keywords": [
      "Electroconvulsive Therapy", 
      "in-patient", 
      "Treatment-Resistant Depressive Disorder", 
      "randomized trial", 
      "ketamine", 
      "patient", 
      "real-world setting", 
      "patient-reported outcome", 
      "primary and secondary outcome measure", 
      "inclusion criterion", 
      "exclusion criterion", 
      "questionnaire", 
      "symptom", 
      "acute treatment phase"
    ], 
    "name": "ELEKT-D: Electroconvulsive Therapy (ECT) vs. Ketamine in Patients With Treatment Resistant Depression (TRD)", 
    "sameAs": [
      "https://app.dimensions.ai/details/clinical_trial/NCT03113968"
    ], 
    "sdDataset": "clinical_trials", 
    "sdDatePublished": "2019-03-07T15:27", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "file:///pack/app/us_ct_data_00024.json", 
    "sponsor": [
      {
        "id": "https://www.grid.ac/institutes/grid.47100.32", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.239578.2", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.430109.f", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.416167.3", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.39382.33", 
        "type": "Organization"
      }
    ], 
    "startDate": "2017-04-01T00:00:00Z", 
    "subjectOf": [
      {
        "id": "sg:pub.10.1038/npp.2016.193", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014772588", 
          "https://doi.org/10.1038/npp.2016.193"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmct075234", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032934964"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1176/appi.ajp.2012.12050648", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1063499741"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1176/appi.ajp.2015.15040465", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1063500640"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1077447843", 
        "type": "CreativeWork"
      }
    ], 
    "type": "MedicalStudy", 
    "url": "https://clinicaltrials.gov/show/NCT03113968"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/clinicaltrial.NCT03113968'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/clinicaltrial.NCT03113968'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/clinicaltrial.NCT03113968'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/clinicaltrial.NCT03113968'


 

This table displays all metadata directly associated to this object as RDF triples.

56 TRIPLES      16 PREDICATES      38 URIs      23 LITERALS      1 BLANK NODES

Subject Predicate Object
1 sg:clinicaltrial.NCT03113968 schema:about anzsrc-for:3053
2 schema:description The goal of the study is to conduct a comparative randomized trial of electroconvulsive therapy (ECT) vs. ketamine for patients with treatment resistant depression (TRD) in a real world setting with patient reported outcomes as primary and secondary outcome measures. Detailed Description Patients with treatment resistant depression who meet all inclusion criteria and do not meet any exclusion criteria will be randomized to either electroconvulsive therapy (ECT) three times per week or ketamine infusion two times per week. Patients will answer questionnaires about their symptoms prior to treatments. The acute treatment phase of the study will last three to five weeks. Depending on response to treatment, some patients will be followed for an additional six months.
3 schema:endDate 2022-04-01T00:00:00Z
4 schema:keywords Electroconvulsive Therapy
5 Treatment-Resistant Depressive Disorder
6 acute treatment phase
7 exclusion criterion
8 in-patient
9 inclusion criterion
10 ketamine
11 patient
12 patient-reported outcome
13 primary and secondary outcome measure
14 questionnaire
15 randomized trial
16 real-world setting
17 symptom
18 schema:name ELEKT-D: Electroconvulsive Therapy (ECT) vs. Ketamine in Patients With Treatment Resistant Depression (TRD)
19 schema:sameAs https://app.dimensions.ai/details/clinical_trial/NCT03113968
20 schema:sdDatePublished 2019-03-07T15:27
21 schema:sdLicense https://scigraph.springernature.com/explorer/license/
22 schema:sdPublisher Nc1683db08ef341a59a941428c1cab4d8
23 schema:sponsor https://www.grid.ac/institutes/grid.239578.2
24 https://www.grid.ac/institutes/grid.39382.33
25 https://www.grid.ac/institutes/grid.416167.3
26 https://www.grid.ac/institutes/grid.430109.f
27 https://www.grid.ac/institutes/grid.47100.32
28 schema:startDate 2017-04-01T00:00:00Z
29 schema:subjectOf sg:pub.10.1038/npp.2016.193
30 https://app.dimensions.ai/details/publication/pub.1077447843
31 https://doi.org/10.1056/nejmct075234
32 https://doi.org/10.1176/appi.ajp.2012.12050648
33 https://doi.org/10.1176/appi.ajp.2015.15040465
34 schema:url https://clinicaltrials.gov/show/NCT03113968
35 sgo:license sg:explorer/license/
36 sgo:sdDataset clinical_trials
37 rdf:type schema:MedicalStudy
38 Nc1683db08ef341a59a941428c1cab4d8 schema:name Springer Nature - SN SciGraph project
39 rdf:type schema:Organization
40 anzsrc-for:3053 schema:inDefinedTermSet anzsrc-for:
41 rdf:type schema:DefinedTerm
42 sg:pub.10.1038/npp.2016.193 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014772588
43 https://doi.org/10.1038/npp.2016.193
44 rdf:type schema:CreativeWork
45 https://app.dimensions.ai/details/publication/pub.1077447843 schema:CreativeWork
46 https://doi.org/10.1056/nejmct075234 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032934964
47 rdf:type schema:CreativeWork
48 https://doi.org/10.1176/appi.ajp.2012.12050648 schema:sameAs https://app.dimensions.ai/details/publication/pub.1063499741
49 rdf:type schema:CreativeWork
50 https://doi.org/10.1176/appi.ajp.2015.15040465 schema:sameAs https://app.dimensions.ai/details/publication/pub.1063500640
51 rdf:type schema:CreativeWork
52 https://www.grid.ac/institutes/grid.239578.2 schema:Organization
53 https://www.grid.ac/institutes/grid.39382.33 schema:Organization
54 https://www.grid.ac/institutes/grid.416167.3 schema:Organization
55 https://www.grid.ac/institutes/grid.430109.f schema:Organization
56 https://www.grid.ac/institutes/grid.47100.32 schema:Organization
 




Preview window. Press ESC to close (or click here)


...